What did the WHI study actually show about HRT?

The Women's Health Initiative (WHI) was a large 2002 trial whose early results were reported as a significant increase in breast-cancer risk among women on hormone therapy. The headline drove a generation of women — and their doctors — away from HRT. The experts who cover it in our dataset don't say the WHI was fabricated; they say it was misinterpreted, and then over-extrapolated far beyond what it actually tested.

The first problem is what was tested. The WHI's combined arm used one specific regimen — conjugated equine estrogen (Premarin) plus the synthetic progestin medroxyprogesterone acetate (MPA) — in an older cohort, often a decade or more past menopause onset. That result was then generalized to all women, all ages, and all formulations, including the transdermal bioidentical estradiol the experts now prefer.

The second problem is relative versus absolute risk. The breast-cancer signal in the combined arm was about a 24-26% relative increase — which sounds alarming — but in absolute terms it amounts to roughly one extra case per 1,000 women per year. Crucially, the estrogen-alone arm showed no increased breast-cancer risk at all. Attia made this case across multiple episodes with the field's leading voices: he hosted the WHI's own lead investigator, JoAnn Manson, as well as Avrum Bluming and Carol Tavris ("Estrogen Matters"); Hyman covered the same ground with OB/GYN Dr. Sharon Malone, and Huberman with Dr. Mary Claire Haver and Dr. Sara Gottfried.

This is why the November 2025 FDA decision to remove HRT's boxed warning for breast cancer, heart disease, and dementia matters: it reflects the modern reading of the WHI plus newer data. The endometrial-cancer warning for systemic estrogen-only therapy stays. None of this makes HRT automatically right for any individual — that's still a clinician conversation — but it reframes the headline that scared everyone off.